Avanos Medical Inc. (NYSE:AVNS) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy and Corporate Development Joseph Woody - CEO Michael Greiner - Senior VP, CFO and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Kristen Stewart - CL King Daniel Stauder - JMP Securities Operator Good morning, and welcome to Avanos' Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Inst ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (Sta ...

Avanos Medical Inc. (NYSE:AVNS) Q2 2023 Results Conference Call August 9, 2023 9:00 AM ET Company Participants Joe Woody - CEO and Director Scott Galovan - Vice President of Strategy and Corporate Development Michael Greiner - Senior VP, CFO and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Kristen Stewart - CL King Daniel Stauder - JMP Securities Operator Good morning, everyone, and welcome to the Avanos Second Quarter 2023 Earnings Conference Call. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or ...

Avanos Medical, Inc. (NYSE:AVNS) Q1 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy and M&A Joe Woody - CEO Michael Greiner - SVP, CFO, and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Drew Ranieri - Morgan Stanley Operator Good morning and welcome to the Avanos Q1 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State o ...

Avanos Medical, Inc. (NYSE:AVNS) Q4 2022 Earnings Conference Call February 21, 2023 9:00 AM ET Company Participants Scott Galovan - Senior Vice President, Strategy and M&A Joe Woody - Chief Executive Officer Michael Greiner - Senior Vice President, Chief Financial Officer and CTO Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Drew Ranieri - Morgan Stanley Dave Turkaly - JMP Securities Operator Good day. And welcome to the Avanos Fourth Quarter 2022 Earnings Conference Call. All par ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to | --- | --- | |-----------------------------------------------------------------------------|-------| | | | | Commission file number: 001-36440 | | | | | | Avan ...

Avanos Medical, Inc. (NYSE:AVNS) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET Company Participants Scott Galovan - Vice President, Corporate Strategy and Business Development Joseph Woody - Chief Executive Officer Michael Greiner - Senior Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Brett Fishbin - KeyBanc Operator Good morning, and welcome to the Avanos Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event ...